Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Phathom Pharmaceuticals, Inc. (PHAT) reported a Q3 loss of $1.32 per share, which was better than the Zacks Consensus Estimate of a $1.57 loss. This is an increase in loss compared to $0.76 per share a year ago.
November 07, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Phathom Pharmaceuticals reported a Q3 loss of $1.32 per share, better than the expected $1.57 loss, but worse than last year's $0.76 loss.
The better-than-expected earnings per share loss may provide some short-term stability or positive sentiment, but the increase in loss compared to last year could offset this, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100